Hurt Aeron C, Barr Ian G, Durrant Christopher J, Shaw Robert P, Sjogren Helen M, Hampson Alan W
WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia.
Commun Dis Intell Q Rep. 2003;27(4):542-7.
Two hundred and forty-five human influenza A and B viruses isolated in Australia between 1996 and 2003 were tested for their sensitivity to the NA inhibitor drugs, zanamivir and oseltamivir using a fluorescence-based neuraminidase inhibition assay. Based on mean IC50 values, influenza A viruses (with neuraminidase subtypes N1 and N2) were more sensitive to both the NA inhibitors than were influenza B strains. Influenza A viruses with a N1 subtype and influenza B strains both demonstrated a greater sensitivity to zanamivir than to oseltamivir carboxylate, whereas influenza A strains with a N2 subtype were more susceptible to oseltamivir carboxylate. A comparison of IC50 values for viruses isolated before and after the release of the NA inhibitors in Australia, found there was no significant difference in the sensitivity of strains to either neuraminidase inhibitor and none of the isolates tested showed clinically significant resistance.
采用基于荧光的神经氨酸酶抑制试验,对1996年至2003年期间在澳大利亚分离出的245株甲型和乙型人流感病毒进行了对神经氨酸酶抑制剂药物扎那米韦和奥司他韦的敏感性测试。根据半数抑制浓度(IC50)均值,甲型流感病毒(神经氨酸酶亚型为N1和N2)对这两种神经氨酸酶抑制剂的敏感性均高于乙型流感毒株。N1亚型甲型流感病毒和乙型流感毒株对扎那米韦的敏感性均高于对羧基奥司他韦的敏感性,而N2亚型甲型流感毒株对羧基奥司他韦更敏感。对澳大利亚神经氨酸酶抑制剂上市前后分离出的病毒的IC50值进行比较,发现毒株对两种神经氨酸酶抑制剂的敏感性均无显著差异,且所测试的分离株均未显示出具有临床意义的耐药性。